Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Phase 3 ◽

Double Blind ◽

A phase 3, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (CheckMate 7DX)

10.26226/morressier.613756f1842293c031b5830d ◽

2021 ◽

Author(s):

Karim Fizazi

Keyword(s):

Prostate Cancer ◽

Double Blind Trial ◽

Phase 3 ◽

Double Blind ◽

Blind Trial ◽

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30898-2 ◽

2019 ◽

Vol 20 (4) ◽

pp. 556-569 ◽

Cited By ~ 30

Author(s):

Bertrand Tombal ◽

Fred Saad ◽

David Penson ◽

Maha Hussain ◽

Cora N Sternberg ◽

...

Keyword(s):

Prostate Cancer ◽

Patient Reported Outcomes ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Patient Reported

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(12)70379-0 ◽

2012 ◽

Vol 13 (10) ◽

pp. 983-992 ◽

Cited By ~ 773

Author(s):

Karim Fizazi ◽

Howard I Scher ◽

Arturo Molina ◽

Christopher J Logothetis ◽

Kim N Chi ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps5081 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS5081-TPS5081 ◽

Cited By ~ 3

Author(s):

James L. Gulley ◽

Jeannie Lorraine Giacchino ◽

James Bradley Breitmeyer ◽

Alexis J. Franzusoff ◽

Dennis Panicali ◽

...

Keyword(s):

Prostate Cancer ◽

Efficacy Study ◽

Phase 3 ◽

Double Blind ◽

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70474-7 ◽

2014 ◽

Vol 15 (12) ◽

pp. 1397-1406 ◽

Cited By ~ 208

Author(s):

Peter Hoskin ◽

Oliver Sartor ◽

Joe M O'Sullivan ◽

Dag Clement Johannessen ◽

Svein I Helle ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Subgroup Analysis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Radium 223

Re: Effect of Radium-223 Dichloride on Symptomatic Skeletal Events in Patients with Castration-Resistant Prostate Cancer and Bone Metastases: Results from a Phase 3, Double-Blind, Randomised Trial

The Journal of Urology ◽

10.1016/j.juro.2014.12.077 ◽

2015 ◽

Vol 193 (3) ◽

pp. 847-848

Author(s):

Samir S. Taneja

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Randomised Trial ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Radium 223

Faculty Opinions recommendation of Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.740905744.793589416 ◽

2021 ◽

Author(s):

Patrick Richard

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)71205-7 ◽

2015 ◽

Vol 16 (2) ◽

pp. 152-160 ◽

Cited By ~ 642

Author(s):

Charles J Ryan ◽

Matthew R Smith ◽

Karim Fizazi ◽

Fred Saad ◽

Peter F A Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

Updated Survival, Quality of Life (QOL), and Safety Data of Radium-223 Chloride (RA-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases from the Phase 3 Double-Blind, Randomized, Multinational Study (ALSYMPCA)

Annals of Oncology ◽

10.1016/s0923-7534(20)33503-1 ◽

2012 ◽

Vol 23 ◽

pp. ix296 ◽

Cited By ~ 7

Author(s):

C. Parker ◽

R.E. Coleman ◽

S. Nilsson ◽

N. Vogelzang ◽

A.J. Lloyd ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Safety Data ◽

Multinational Study ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Radium 223

MP52-20 PATIENT REPORTED OUTCOMES (PROS) IN SPARTAN, A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF APALUTAMIDE (APA) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VS PLACEBO PLUS ADT IN MEN WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)

The Journal of Urology ◽

10.1016/j.juro.2018.02.1671 ◽

2018 ◽

Vol 199 (4S) ◽

Cited By ~ 1

Author(s):

Eric J. Small ◽

Fred Saad ◽

Boris A. Hadaschik ◽

Julie N. Graff ◽

Paul N. Mainwaring ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Patient Reported Outcomes ◽

Randomized Study ◽

Androgen Deprivation ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Patient Reported